Back to Search
TIMOTHY CURLEY, MD
MD
Nephrology Physician
NPI: 1952400970IndividualAccepts Medicare
Specialties, Licenses & Credentials
Nephrology PhysicianPrimary
Internal Medicine — Nephrology
Code: 207RN0300X
033821(CT)
Education
CHICAGO COLLEGE OF OSTEOPATHY
Class of 1997
Research & Publications (18)
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.
PMID 19375217·Eur Urol·2009
3-trial
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
PMID 19364960·J Clin Oncol·2009
3-trial
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
PMID 18565882·J Clin Oncol·2008
3-trial
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
PMID 17363532·Clin Cancer Res·2007
3-trial
Rapid androgen cycling as treatment for patients with prostate cancer.
PMID 17189414·Clin Cancer Res·2006
3-trial
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
PMID 16512979·Clin Lung Cancer·2006
3-trial
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.
PMID 16243819·Clin Cancer Res·2005
3-trial
A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy.
PMID 15954919·Kidney Int·2005
3-trial
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
PMID 15897550·J Clin Oncol·2005
3-trial
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
PMID 15735119·J Clin Oncol·2005
3-trial
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
PMID 15112267·Cancer·2004
4-observational
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
PMID 14584065·Cancer·2003
3-trial
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
PMID 14506144·Clin Cancer Res·2003
3-trial
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
PMID 12796374·Clin Cancer Res·2003
3-trial
Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial.
PMID 12559285·Urology·2003
3-trial
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.
PMID 11134194·J Clin Oncol·2001
3-trial
The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer.
PMID 10741705·Clin Cancer Res·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 85 SEYMOUR ST
HARTFORD, CT 06106 - Phone
- (860) 241-0700
Quick Facts
- NPI
- 1952400970
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 29
- Publications
- 18
Are you this provider?
Claim Your Profile